Unlike GLP-1, GIP also reduces acid production in the stomach, which slows down the digestion of food, and restores the bodys sensitivity to insulin, says Dr
78 Early 2a studies in patients with NASH and metabolic risk factors showed that efruxifermin rapidly reduced liver fat, improved triglycerides and HDL cholesterol, and increased adiponectin
GLP-1 Market Size: USD 68.65 billion in 2026 | USD 195.01 billion by 2035 | CAGR: 12.3% | Leading Molecule: Semaglutide ( 52.1% revenue share) | Dominant Region: United States ( 62.8% revenue share) GLP-1 Weight Loss Drug Market Highlights: Key Data at a Glance ( 2026 ) GLP-1 Weight Loss Drug Market Size 2026 : USD 68.65 billion , forecast USD 195.01 billion by 2035 at 12.3% CAGR Dominant drug class: Dual GIP/GLP-1 Agonists (tirzepatide) and Injectable GLP-1 RA Monoagonists (semaglutide) with 78.4% combined revenue share Fastest-growing route: Oral GLP-1 formulations at 34.2% CAGR through 2035 driven by injection-free patient access expansion GLP-1 market leaders: Novo Nordisk and Eli Lilly with approximately 87% combined prescription weight management drug revenue share in 2026 Most prescribed weight loss molecule: Semaglutide (Wegovy and Ozempic) with 52.1% global GLP-1 market revenue share in 2026 FDA-approved anti-obesity GLP-1 drugs: Four molecules including semaglutide, tirzepatide, liraglutide, and oral semaglutide as of 2026 Global obesity patient pool: More than 1.1 billion adults with obesity globally
Our approach With decades of operating experience, Dr
Diabetologia, 41 (4), 307-313
Both DHA and EPA act as natural ligands for various nuclear receptors, including peroxisome proliferator-activated receptors, which are abundantly present in microglia and pivotal for the transcriptional regulation of many cellular activities, such as lipid balance and inflammation control (54)
